Docetaxel Accord
Docetaxel (as trihydrate) – Taxoid Antineoplastic Agent for Cancer Treatment
Docetaxel Accord is a chemotherapy medicine containing the active substance docetaxel, a taxoid antineoplastic agent originally derived from the needles of the European yew tree. It is used to treat several types of cancer, including breast cancer, non-small cell lung cancer, prostate cancer, gastric (stomach) cancer, and head and neck cancer. Docetaxel works by disrupting cancer cell division, preventing tumors from growing and spreading. It is administered as an intravenous infusion in a hospital setting under specialist supervision.
Quick Facts
Key Takeaways
- Docetaxel Accord is a chemotherapy drug used to treat breast, lung, prostate, gastric, and head and neck cancers, either alone or in combination with other agents.
- It must be administered intravenously in a hospital by healthcare professionals experienced in cancer treatment, typically every three weeks.
- Premedication with oral corticosteroids (e.g., dexamethasone) starting the day before infusion is mandatory to reduce the risk of hypersensitivity reactions and fluid retention.
- Common side effects include neutropenia, hair loss, nausea, mouth sores, and fatigue; regular blood tests are required to monitor blood counts and liver function.
- The formulation contains ethanol (alcohol), which must be considered for patients with alcohol dependence, epilepsy, liver disease, or during pregnancy.
What Is Docetaxel Accord and What Is It Used For?
Docetaxel Accord contains the active substance docetaxel (as trihydrate), a potent antineoplastic (anticancer) agent that belongs to the taxoid class of chemotherapy drugs. Taxoids are among the most widely used classes of anticancer agents worldwide, and docetaxel specifically has been a cornerstone of oncology treatment since its approval by the European Medicines Agency (EMA). The drug works at the cellular level by interfering with the ability of cancer cells to divide and multiply, ultimately leading to cell death.
The mechanism of action of docetaxel involves promoting the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Microtubules are essential structural components of cells that play a critical role during cell division (mitosis). By stabilizing these microtubules, docetaxel effectively "freezes" the cell's internal skeleton, preventing the normal reorganization required for a cell to divide. This results in an accumulation of non-functional microtubule bundles and ultimately triggers programmed cell death (apoptosis) in rapidly dividing cancer cells.
Docetaxel Accord is prescribed for the treatment of several major cancer types. In advanced breast cancer, it can be administered as a single agent or in combination with doxorubicin, trastuzumab, or capecitabine, depending on the specific clinical scenario and prior treatment history. For early-stage breast cancer, whether or not lymph nodes are involved, docetaxel is used in combination with doxorubicin and cyclophosphamide (the TAC regimen), a well-established adjuvant chemotherapy protocol supported by large-scale clinical trials.
In non-small cell lung cancer (NSCLC), docetaxel can be used either as monotherapy in patients who have progressed after prior platinum-based chemotherapy, or as first-line therapy in combination with cisplatin. For metastatic castration-resistant prostate cancer, docetaxel is given in combination with prednisone or prednisolone and remains a standard first-line chemotherapy option. In gastric adenocarcinoma, it is used in combination with cisplatin and 5-fluorouracil (the DCF regimen). For squamous cell carcinoma of the head and neck, docetaxel is used with cisplatin and 5-fluorouracil as induction chemotherapy before definitive local treatment.
As a generic formulation manufactured by Accord Healthcare, Docetaxel Accord contains the same active substance as the originator product and has been approved by regulatory authorities following rigorous bioequivalence studies. It is available in three vial sizes: 20 mg/1 mL, 80 mg/4 mL, and 160 mg/8 mL concentrate for solution for infusion, allowing flexible dosing based on individual patient body surface area calculations.
What Should You Know Before Taking Docetaxel Accord?
Contraindications
Docetaxel Accord is contraindicated (must not be used) in patients who have a known hypersensitivity (allergy) to docetaxel or any of the excipients in the formulation, including polysorbate 80, ethanol, or citric acid. Patients who have experienced severe allergic reactions to paclitaxel (another taxoid agent) should inform their oncologist, as cross-reactivity may occur, and any subsequent allergic reaction to docetaxel could potentially be more severe.
The medicine must not be administered if the patient's neutrophil count is below 1,500 cells/mm³. Neutrophils are a type of white blood cell essential for fighting infections, and administering docetaxel to a patient with already compromised neutrophil levels would create an unacceptable risk of severe, potentially life-threatening infections. Additionally, docetaxel is contraindicated in patients with severe hepatic (liver) impairment, as the liver is the primary organ responsible for metabolizing docetaxel, and impaired liver function can lead to dangerously elevated drug concentrations and increased toxicity.
Warnings and Precautions
Before each cycle of treatment, blood tests will be performed to ensure adequate blood cell counts (including white blood cells, red blood cells, and platelets) and sufficient liver function. Docetaxel commonly causes neutropenia (a decrease in neutrophils), which may be accompanied by fever (febrile neutropenia) or clinical infections requiring prompt medical attention.
- Abdominal pain or tenderness, diarrhea, rectal bleeding, blood in stool, or fever – these may indicate serious gastrointestinal injury that can be life-threatening
- Vision problems, especially blurred vision – requires immediate ophthalmological evaluation
- Fever, shortness of breath, or persistent cough – may indicate lung complications
- Severe skin reactions including blistering, peeling, or bleeding of skin, mouth, eyes, or genitals – may indicate Stevens-Johnson syndrome or toxic epidermal necrolysis
- Irregular or rapid heartbeat, severe dizziness, or fainting – may indicate cardiac arrhythmia
Patients with a history of cardiac problems should inform their oncologist before starting therapy, as docetaxel has been associated with cardiac events including heart failure and ventricular arrhythmias. Those who develop acute or worsening pulmonary symptoms (fever, shortness of breath, or cough) must report them immediately, as interstitial lung disease, pneumonitis, and pulmonary fibrosis have been reported with docetaxel use.
Corticosteroid premedication is mandatory before each docetaxel infusion. Patients should take an oral corticosteroid such as dexamethasone starting the day before the infusion and continuing for 1 to 2 days after. This premedication significantly reduces the incidence and severity of hypersensitivity reactions and fluid retention (swelling of hands, feet, legs, or weight gain).
Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported. SJS and TEN present as blistering, peeling, or bleeding on any part of the skin, often accompanied by flu-like symptoms. AGEP manifests as a widespread red, scaly rash with bumps under swollen skin, accompanied by fever. Any such reactions require immediate discontinuation of treatment and urgent medical care.
Patients with kidney problems or elevated uric acid levels should inform their physician before treatment, as tumor lysis syndrome has been reported with docetaxel. This serious condition involves the rapid release of cellular contents into the bloodstream following cancer cell destruction and can lead to kidney failure, seizures, and cardiac arrhythmias.
Pregnancy and Breastfeeding
Docetaxel Accord must not be used during pregnancy unless the potential benefit to the mother clearly outweighs the risk to the fetus, as docetaxel may cause serious harm to the developing baby. Women of childbearing potential must use effective contraception throughout treatment. If pregnancy occurs during therapy, the treating physician must be informed immediately.
Male patients being treated with docetaxel are advised not to father a child during treatment and for at least 6 months after the final dose. Consultation regarding sperm preservation before beginning therapy is recommended, as docetaxel may affect male fertility. Breastfeeding is contraindicated during docetaxel treatment.
Alcohol Content
The formulation contains 50% v/v anhydrous ethanol. The 20 mg/1 mL vial contains approximately 395 mg of ethanol (equivalent to approximately 10 mL of beer or 4 mL of wine). Higher-volume vials contain proportionally more ethanol. This alcohol content is clinically relevant for patients with alcohol dependence, epilepsy, liver disease, pregnant or breastfeeding women, and children. It may also impair the ability to drive or operate machinery and can affect the central nervous system.
How Does Docetaxel Accord Interact with Other Drugs?
Drug interactions with docetaxel can be clinically significant because the drug is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme in the liver. Concomitant use of medications that inhibit or induce this enzyme can substantially affect docetaxel plasma concentrations, potentially leading to increased toxicity or reduced therapeutic efficacy. Your oncologist should be informed of all medications you are currently taking, have recently taken, or plan to take, including prescription drugs, over-the-counter medicines, and herbal supplements.
CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, erythromycin, and ritonavir can decrease the metabolic clearance of docetaxel, leading to increased drug exposure and a higher risk of adverse effects. If concomitant use of strong CYP3A4 inhibitors is unavoidable, close monitoring and potential dose adjustments may be required. Grapefruit juice is also a known CYP3A4 inhibitor and should be avoided during treatment.
CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's wort (Hypericum perforatum) can increase the metabolism of docetaxel, potentially reducing its plasma levels and therapeutic effectiveness. Patients should be specifically asked about the use of herbal supplements, as St. John's wort is commonly used without medical supervision.
| Interacting Drug / Class | Effect on Docetaxel | Clinical Significance | Recommendation |
|---|---|---|---|
| Ketoconazole, itraconazole | Increased docetaxel levels (CYP3A4 inhibition) | Major – increased toxicity risk | Avoid combination or adjust dose |
| Erythromycin, clarithromycin | Increased docetaxel levels (CYP3A4 inhibition) | Major – increased toxicity risk | Monitor closely; consider alternatives |
| Rifampicin | Decreased docetaxel levels (CYP3A4 induction) | Major – reduced efficacy | Avoid concomitant use |
| Phenytoin, carbamazepine | Decreased docetaxel levels (CYP3A4 induction) | Moderate – potentially reduced efficacy | Monitor response; dose adjustment may be needed |
| St. John's wort | Decreased docetaxel levels (CYP3A4 induction) | Major – reduced efficacy | Discontinue before treatment |
| Ritonavir, other protease inhibitors | Increased docetaxel levels (CYP3A4 inhibition) | Major – increased toxicity risk | Avoid combination if possible |
| Grapefruit juice | Increased docetaxel levels (CYP3A4 inhibition) | Moderate | Avoid during treatment |
Additionally, the alcohol content in Docetaxel Accord may interact with other medications and potentially alter their effects. Patients receiving concurrent medications that affect the central nervous system should be monitored for additive sedative effects. When docetaxel is used as part of combination chemotherapy regimens (e.g., with cisplatin, doxorubicin, or 5-fluorouracil), the overlapping toxicity profiles of each agent must be carefully managed, and dose modifications may be necessary based on the severity of adverse reactions.
What Is the Correct Dosage of Docetaxel Accord?
Docetaxel Accord must only be administered by or under the direct supervision of a qualified oncologist experienced in the use of antineoplastic agents. The dose is individualized based on the patient's body surface area (BSA), calculated in square meters (m²) using the patient's height and weight. Before each cycle, the oncologist evaluates blood test results, overall clinical condition, and any side effects from the previous cycle to determine whether the dose needs to be adjusted or treatment should be postponed.
Dosage by Cancer Type
| Cancer Type | Docetaxel Dose | Combination Agents | Cycle Interval |
|---|---|---|---|
| Breast cancer (advanced, monotherapy) | 75–100 mg/m² | Single agent | Every 3 weeks |
| Breast cancer (adjuvant, TAC) | 75 mg/m² | Doxorubicin + Cyclophosphamide | Every 3 weeks (6 cycles) |
| Breast cancer (with trastuzumab) | 100 mg/m² | Trastuzumab | Every 3 weeks |
| Breast cancer (with capecitabine) | 75 mg/m² | Capecitabine | Every 3 weeks |
| NSCLC (monotherapy) | 75 mg/m² | Single agent | Every 3 weeks |
| NSCLC (with cisplatin) | 75 mg/m² | Cisplatin | Every 3 weeks |
| Prostate cancer | 75 mg/m² | Prednisone or Prednisolone | Every 3 weeks |
| Gastric cancer | 75 mg/m² | Cisplatin + 5-Fluorouracil | Every 3 weeks |
| Head & neck cancer | 75 mg/m² | Cisplatin + 5-Fluorouracil | Every 3 weeks |
Administration Method
Docetaxel Accord is administered as an intravenous infusion over approximately one hour. It must not be given as a bolus injection. The concentrate is diluted in a 250 mL infusion bag containing either 5% glucose solution or 0.9% sodium chloride solution. If a dose greater than 190 mg is required, a larger volume of infusion fluid is used to ensure the docetaxel concentration does not exceed 0.74 mg/mL. The infusion must be given in a healthcare facility equipped to manage potential infusion-related reactions.
Dose Modifications
Your oncologist may modify the dose or delay treatment cycles based on how your body responds to the therapy. Dose reductions are commonly required for:
- Febrile neutropenia or severe neutropenia lasting more than 7 days
- Severe peripheral neuropathy (numbness, tingling, or pain in hands or feet)
- Severe mucositis (mouth sores of Grade 3 or 4 severity)
- Cumulative fluid retention not responsive to supportive measures
- Other Grade 3–4 non-hematologic toxicities
It is critically important that patients report all symptoms to their treatment team, including diarrhea, mouth sores, numbness or tingling, and fever. This information directly informs dosing decisions and helps ensure the safest possible treatment course. Blood test results between cycles are also essential for dose optimization.
Premedication Protocol
Required Corticosteroid Premedication
An oral corticosteroid such as dexamethasone 16 mg/day (e.g., 8 mg twice daily) must be started the day before each docetaxel infusion and continued for 1–2 days afterwards. This premedication is essential to reduce the incidence and severity of hypersensitivity reactions and fluid retention. Your oncologist may adjust this protocol based on individual patient factors.
What Are the Side Effects of Docetaxel Accord?
As with all medicines, Docetaxel Accord can cause side effects, although not everyone will experience them. Your oncologist will discuss these with you and explain the potential risks and benefits of treatment. The severity and frequency of side effects can vary depending on the dose, whether docetaxel is used as a single agent or in combination with other drugs, and individual patient factors.
Allergic (infusion-related) reactions may occur during the infusion itself. These are reported in more than 1 in 10 patients and can include facial flushing, skin reactions, itching, chest tightness, difficulty breathing, fever, chills, back pain, and low blood pressure. More severe anaphylactic reactions can also occur. Your condition will be closely monitored during each infusion, and you should inform the healthcare team immediately if you notice any of these symptoms.
Between treatment cycles, the following side effects may occur at varying frequencies. The side effects are categorized below by how commonly they occur:
Very Common
- Infections and decreased white blood cell count (neutropenia)
- Anemia (low red blood cells) and low platelet count
- Fever (contact your doctor immediately)
- Loss of appetite
- Insomnia
- Peripheral neuropathy (numbness, tingling, pain in hands/feet)
- Headache and taste changes
- Eye inflammation, increased tearing
- Lymphedema (swelling from poor lymph drainage)
- Shortness of breath, nasal congestion, cough, nosebleeds
- Mouth sores (stomatitis)
- Nausea, vomiting, diarrhea, constipation, stomach pain
- Indigestion
- Hair loss (alopecia) – hair typically regrows after treatment
- Hand-foot syndrome (redness, swelling, peeling of palms and soles)
- Nail changes and possible nail detachment
- Muscle pain, back pain, bone pain
- Menstrual irregularities
- Swelling of hands, feet, and legs (fluid retention)
- Fatigue and flu-like symptoms
- Weight changes
- Upper respiratory tract infections
Common
- Oral candidiasis (fungal mouth infection)
- Dehydration
- Dizziness
- Hearing impairment
- Low blood pressure, irregular or rapid heartbeat
- Heart failure
- Esophagitis (inflammation of the food pipe)
- Dry mouth, difficulty or pain when swallowing
- Increased bleeding tendency
- Elevated liver enzymes
- Increased blood sugar (diabetes)
- Low potassium, calcium, or phosphate levels
Uncommon
- Fainting
- Skin reactions, phlebitis (vein inflammation), and swelling at the injection site
- Blood clots (thromboembolism)
- Acute myeloid leukemia or myelodysplastic syndrome (secondary blood cancers, typically with combination therapy)
Rare
- Colitis or enterocolitis (bowel inflammation, potentially fatal)
- Intestinal perforation
Not Known
- Interstitial lung disease (lung inflammation causing cough and breathing difficulty)
- Pneumonia, pulmonary fibrosis
- Cystoid macular edema (blurred vision from retinal swelling)
- Low sodium or magnesium levels
- Ventricular arrhythmia or ventricular tachycardia (abnormal heart rhythms)
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Acute generalized exanthematous pustulosis (AGEP)
- Tumor lysis syndrome (rapid cancer cell breakdown causing metabolic abnormalities)
- Myositis (muscle inflammation)
- Non-Hodgkin lymphoma and other secondary cancers (with combination therapy)
It is important to report suspected side effects after the medicine has been authorized. This helps to continuously monitor the benefit-risk balance of the medicine. Healthcare professionals and patients can report suspected adverse reactions to their national pharmacovigilance authority (e.g., the EMA in Europe, the FDA in the United States, the MHRA in the United Kingdom).
How Should You Store Docetaxel Accord?
As a hospital-administered medicine, Docetaxel Accord is stored and handled by healthcare professionals. However, understanding proper storage conditions is important for ensuring the medicine remains effective and safe.
Unopened vials should be stored at temperatures not exceeding 25°C and kept in the original carton to protect from light. The medicine should not be used after the expiry date printed on the outer carton and vial label. The expiry date refers to the last day of the stated month. As with all medications, Docetaxel Accord must be kept out of the sight and reach of children.
Once a vial has been opened, it should be used immediately. If not used at once, in-use storage times and conditions are the responsibility of the user. Dilution into infusion bags must be performed under controlled and aseptic (sterile) conditions. Once added to the infusion bag, the solution should be used within 6 hours at room temperature (up to 25°C), including the one-hour infusion time. Physical and chemical stability of the prepared infusion solution has been demonstrated for up to 48 hours when stored at 2–8°C in non-PVC bags.
The docetaxel infusion solution is supersaturated and may crystallize over time. If crystals appear, the solution must not be used and should be disposed of properly. Similarly, solutions showing any precipitate or particles must be discarded. All materials used for dilution and administration should be treated as cytotoxic waste and disposed of according to local institutional policies and regulations.
What Does Docetaxel Accord Contain?
Each milliliter of Docetaxel Accord concentrate for solution for infusion contains 20 mg of docetaxel (as trihydrate). The medicine is available in three vial sizes to allow flexible dosing:
- 20 mg/1 mL – supplied in a 5 mL glass vial with a fluoroplast-coated rubber stopper, aluminum crimp, and orange flip-off cap
- 80 mg/4 mL – supplied in a 5 mL glass vial with a fluoroplast-coated rubber stopper, aluminum crimp, and red flip-off cap
- 160 mg/8 mL – supplied in a 10 mL glass vial with a fluoroplast-coated rubber stopper, aluminum crimp, and red flip-off cap
The excipients (inactive ingredients) are:
- Polysorbate 80 – a surfactant that helps keep docetaxel in solution
- Anhydrous ethanol (50% v/v) – a co-solvent (see section on alcohol content for clinical implications)
- Anhydrous citric acid – a pH-adjusting agent
The concentrate appears as a clear, pale yellow to brownish-yellow solution. It is important to note that Docetaxel Accord is a ready-to-dilute formulation that does not require prior reconstitution with a separate solvent. This distinguishes it from some other docetaxel formulations that come as two-vial systems requiring a reconstitution step before final dilution. More than one vial may be needed to obtain the required dose for a given patient. For example, a dose of 140 mg of docetaxel would require 7 mL of the concentrate.
The prepared infusion solution should be administered using non-PVC infusion sets and bags. The infusion line should be connected for no more than 6 hours at 25°C. Visual inspection of the solution for particulate matter and crystallization should be performed before administration; any solution showing precipitation must be discarded.
Frequently Asked Questions About Docetaxel Accord
Docetaxel Accord is used to treat several types of cancer including breast cancer (both early-stage and advanced/metastatic), non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer, gastric (stomach) adenocarcinoma, and squamous cell carcinoma of the head and neck. Depending on the cancer type and stage, it may be used as a single agent or in combination with other chemotherapy drugs such as doxorubicin, cyclophosphamide, cisplatin, 5-fluorouracil, trastuzumab, capecitabine, prednisone, or prednisolone.
Each Docetaxel Accord infusion takes approximately one hour. It is given as an intravenous drip in a hospital or infusion center. The treatment is typically administered once every three weeks, though your oncologist may adjust the schedule based on your response and tolerance. You will need to arrive ahead of the scheduled infusion time for pre-infusion assessments and should plan to stay for observation after the infusion is complete.
Dexamethasone (a corticosteroid) is taken as a mandatory premedication starting the day before each docetaxel infusion and continuing for 1–2 days afterwards. Its purpose is to reduce the risk and severity of two key side effects: hypersensitivity (allergic) reactions during the infusion and fluid retention (swelling and weight gain) that can occur with repeated cycles. Clinical evidence clearly shows that corticosteroid premedication significantly improves tolerability of docetaxel treatment.
Hair loss (alopecia) is one of the most common side effects of docetaxel and affects the majority of patients. Hair loss typically begins within the first few weeks of treatment and may include hair on the head, eyelashes, eyebrows, and body hair. In most cases, hair begins to regrow after treatment is completed, usually within a few months. However, in some cases (frequency not precisely known), permanent or long-lasting hair thinning has been observed. Scalp cooling caps may help reduce hair loss in some patients and can be discussed with your treatment team.
The alcohol content in Docetaxel Accord may impair your ability to drive or operate machinery. Additionally, side effects such as fatigue, dizziness, and peripheral neuropathy (numbness in hands and feet) can affect your coordination and reaction times. It is generally advisable to arrange for someone else to drive you home after your infusion and to avoid driving or operating machinery until you know how the treatment affects you. Always discuss this with your oncologist or nurse before your first treatment session.
Yes, Docetaxel Accord contains anhydrous ethanol at a concentration of 50% v/v. The 20 mg/1 mL vial contains approximately 395 mg of ethanol (roughly equivalent to 10 mL of beer or 4 mL of wine). The 80 mg/4 mL vial contains about 1.58 g of ethanol, and the 160 mg/8 mL vial contains about 3.16 g. This is clinically relevant for patients with alcohol dependence, epilepsy, liver disease, and for pregnant or breastfeeding women. It should also be factored into considerations about driving and operating machinery after infusion.
References
This article is based on the following peer-reviewed and authoritative sources:
- European Medicines Agency (EMA). Docetaxel – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Accessed February 2026.
- Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treatment Reviews. 2003;29(5):407–415. doi:10.1016/S0305-7372(03)00097-5
- ESMO Clinical Practice Guidelines: Breast Cancer, Lung Cancer, Prostate Cancer. European Society for Medical Oncology. Available at: www.esmo.org/guidelines.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Available at: www.nccn.org.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. European Journal of Oncology Nursing. 2009;13(1):49–59. doi:10.1016/j.ejon.2008.10.003
- Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513–2531.
- British National Formulary (BNF). Docetaxel monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in oncology, clinical pharmacology, and evidence-based medicine. All content follows international medical guidelines and the GRADE evidence framework.
All medical information is reviewed by oncology specialists with clinical experience in cancer chemotherapy, ensuring accuracy and relevance to current treatment standards.
Content is based on Level 1A evidence from systematic reviews, randomized controlled trials, EMA-approved product information, and internationally recognized clinical practice guidelines (ESMO, NCCN).
iMedic receives no funding from pharmaceutical companies. All content is independently produced and free from commercial influence. Our editorial standards, review process, and conflict-of-interest policies are publicly available on our Editorial Standards page.